In 2005, after the transcriptomic profiling of BC, Farmer et al. described a new subtype of BC that is characterized by a luminal expression profile without ER but AR overexpression, as well as with a morphological apocrine differentiation (which was designated by the term molecular apocrine breast cancer (MABC) [23]). Here, AR is linked to breast carcinoma.